-

Bruker Highlights New Analytical Systems and Applied Market Solutions

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) this week highlights new analytical systems and high-value solutions for biopharma and forensics applications, as well as for industrial process control and materials science research. Originally, Bruker had planned to launch these products at Analytica 2020 this week. However, with conferences and tradeshows postponed or cancelled due to COVID-19, Bruker remains committed to the success of its customers, and is proceeding with on-line launches at this time.

OMEGA 5 FTIR Gas Analyzer: OMEGA 5 is a new Fourier Transform Infrared (FTIR) gas analyzer that is rackmounted and equipped with a multi-reflection gas cell of 5 m optical path length. It allows automated, precision and real-time monitoring of gas concentrations even in mixtures. The OMEGA 5 is designed for applications like process monitoring, the investigation of catalytic processes, or the determination of gas impurities. More info

FOURIER™ CrimeLab – Benchtop FT-NMR for Forensic Laboratories: Bruker envisions that interconnected high-field NMR spectrometers at central forensic laboratories and benchtop FOURIER CrimeLab 80 MHz FT-NMRs at local labs will enable law enforcement to unambiguously identify suspicious known or new psychoactive substances. Benchtop FT-NMR is made easy for novices by the new push-button, non-expert software GoScan. Please watch our recorded webinar

S2 PUMA™ - Benchtop X-Ray Elemental Analyzer: the next-generation benchtop Energy Dispersive X-Ray Fluorescence (EDXRF) spectrometer S2 PUMATM Series 2 is equipped with HighSenseTM technology for increases in throughput by about a factor of 3x. Bruker’s software SPECTRA.ELEMENTSTM comes with enhanced features and faster algorithms, leading to ~40% shorter evaluation times. The S2 PUMA Series 2 supports elemental analysis applications from cement, steel, mining and petrochemical, to food analysis and pharma QC. The new mapping stage also extends its applications into semiconductors and coatings, where spatial resolution is required. Please watch our recorded webinar

Sierra SPR-24 Pro – Biopharma ‘Workhorse’: Bruker expands its Surface Plasmon Resonance (SPR) product line with the Sierra SPR-24 Pro, which complements the highest-performance Sierra SPR-32. The new, robust SPR-24 Pro offers high performance and throughput for biopharma applications such as antibody characterization, protein-protein and protein-small molecule interactions, fragment screening, etc. It offers an 8-channel, 3-sensor-spot design (i.e. 24 addressable spots) with automated operation by robotic plate handling for further increases in SPR throughput. Please watch our upcoming webinar

Other on-demand and upcoming webinars on a wide range of applications can be can be found at www.bruker.com/webinars

About Bruker Corporation (Nasdaq: BRKR)

Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular research, in applied and pharma applications, in microscopy and nanoanalysis, and in industrial applications, as well as in cell biology, preclinical imaging, clinical phenomics and proteomics research and clinical microbiology. For more information, please visit: www.bruker.com.

Contacts

Investor Contact:
Miroslava Minkova
Director, Investor Relations & Corporate Development
T: +1 (978) 663-3660 x1479
E: investor.relations@bruker.com

Media Contact:
Dr. Thorsten Thiel
VP of Group Marketing
T: +49 (721) 5161–6500
E: thorsten.thiel@bruker.com

Bruker Corporation

NASDAQ:BRKR

Release Summary
Bruker Highlights New Analytical Systems and Applied Market Solutions
Release Versions

Contacts

Investor Contact:
Miroslava Minkova
Director, Investor Relations & Corporate Development
T: +1 (978) 663-3660 x1479
E: investor.relations@bruker.com

Media Contact:
Dr. Thorsten Thiel
VP of Group Marketing
T: +49 (721) 5161–6500
E: thorsten.thiel@bruker.com

More News From Bruker Corporation

Bruker Announces Date and Time of Second Quarter 2026 Earnings Release and Webcast

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced it will report second quarter 2026 financial results before market opening on Tuesday, August 4, 2026. The Company will host a conference call and webcast at 9:00 a.m. Eastern Daylight Time to discuss the results and current business trends. To listen to the webcast, investors can go to https://ir.bruker.com and click on the “Q2 2026 Earnings Webcast” hyperlink in the “Events & Presentations” section. A sli...

Bruker Expands Infection Detection Portfolio with Acquisition of Metagenomic mNGS DISQVER® Platform for Pathogenic Microorganisms in Blood

BREMEN, Germany--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced the acquisition of the DISQVER® clinical metagenomics platform from Noscendo GmbH.DISQVER® enables metagenomic next-generation sequencing (mNGS) analysis of microbes directly from blood samples, further expanding Bruker's NGS-based infection detection capabilities. Without any need for prior cultivation, DISQVER analyzes whole genome sequencing (WGS) data and applies advanced, proprietary bioinformatics to search...

Bruker Showcases Expanding Microbiology & Infection Diagnostics Portfolio at ASM Microbe 2026

WASHINGTON--(BUSINESS WIRE)--At ASM Microbe 2026, Bruker Corporation’s (Nasdaq: BRKR) Microbiology & Infection Diagnostics (BMID) division is demonstrating its expanding portfolio and innovations across microbial identification, sepsis diagnostics, molecular testing, and NGS workflows, advancing clinical research, and faster, actionable infectious disease diagnostics. During the ASM 2026 meeting, Bruker showcases the expanded clinical capabilities of the MALDI Biotyper® CA System enabled by...
Back to Newsroom